Why Rhythm Pharmaceuticals, Inc. (RYTM) stock moved
Rhythm Pharmaceuticals, Inc. (RYTM) shares tumbled 9.9% to $84.16 as of November 3, 2026, a significant decline from the prior close of $93.44. BestStocks flagged the session as a major change for RYTM. The move is tied to an earnings beat. Below, we break down what changed for RYTM, why it matters for investors, how the stock reacted, and the catalysts on the calendar.
Earnings Beat
Rhythm Pharmaceuticals, Inc. (RYTM) reported EPS of −$0.61 vs. −$0.71 consensus estimate, beating expectations by 14.0% on 2026-11-03. RYTM earnings on 2027-02-25 for confirmation of whether the loss-reduction trend continues.
What it means for Rhythm Pharmaceuticals, Inc. investors
For Rhythm Pharmaceuticals, Inc. investors, the recent signals add up to a strong bearish shift. On the constructive side: Earnings beat — stock sold off (sell-the-news reaction); Rhythm Pharmaceuticals, Inc. (RYTM) moved +5.52% from $100.25 to $105.78 on 2026-08-04. Weighing against that: Sharp 9.9% decline — elevated risk; High volume 3.1x on decline — distribution signal. Wall Street's consensus price target sits at $144.43, implying +71.6% upside from $84.16. BestStocks rates the overall signal quality high (90/100). With earnings roughly 114 days out, the next report is the most likely near-term test of the move.
RYTM price reaction
RYTM last traded at $84.16, down $9.28 (-9.93%) from the previous close of $93.44. The session traded on 3.1× average volume (extreme), so the move carried above-average conviction.
Bullish and bearish analyst opinions on Rhythm Pharmaceuticals, Inc. (RYTM)
The consensus analyst price target on Rhythm Pharmaceuticals, Inc. (RYTM) is $144.43, 71.6% above the recent $84.16. Over the past 90 days analysts logged 0 upgrades, 7 maintains, and 0 downgrades. Here is how the bullish and bearish cases on RYTM line up.
The bullish case
- Wall Street's consensus price target of $144.43 implies +71.6% upside from $84.16.
- The Street's most bullish target is $160.00 (+90.1%).
- Earnings beat — stock sold off (sell-the-news reaction).
- Rhythm Pharmaceuticals, Inc. (RYTM) moved +5.52% from $100.25 to $105.78 on 2026-08-04.
The bearish case
- Sharp 9.9% decline — elevated risk.
- High volume 3.1x on decline — distribution signal.
- Rhythm Pharmaceuticals reported earnings today, triggering a 10.24% intraday decline to $83.87 from $93.44 (FMP delayed intraday).
Weighing both sides, BestStocks' composite read of recent signals is strongly bearish, as the bull-versus-bear meter above shows. This is an educational summary of the bull and bear case, not investment advice.
Analyst price targets and ratings are FMP consensus figures as of Nov 3, 2026; other aggregators may differ. High and low targets show the range of estimates, not forecasts.
Previous notable changes for RYTM
Frequently asked questions about RYTM
Why did Rhythm Pharmaceuticals, Inc. (RYTM) stock move?
RYTM tumbled 9.9% to $84.16. The move is associated with an earnings beat.
How much did RYTM stock fall?
RYTM lost 9.93% ($9.28) versus the prior close of $93.44, last trading at $84.16 on 3.1× average volume.
When is Rhythm Pharmaceuticals, Inc.'s next earnings date?
RYTM's next earnings report is estimated for 2027-02-25 — about 114 days away.
What is the analyst price target for RYTM?
The consensus analyst price target for RYTM is $144.43, about 71.6% above the current $84.16. Over the past 90 days, analysts recorded 0 upgrades, 7 maintains, and 0 downgrades.
How BestStocks tracks RYTM
This page is generated automatically by BestStocks' change-detection system after an earnings beat was detected and verified against independent data sources. It draws on 20 tracked change events for RYTM, cross-checked against the data sources listed below. Price, volume, and market-capitalization figures are the live intraday quote as of November 3, 2026 and refresh as new information is detected; for companies with multiple share classes, market-cap figures can differ by data source. Analyst price targets and ratings are FMP consensus. This is an educational summary of what changed and why — not personalized investment advice.